Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Debt to Equity (2020 - 2023)

Candel Therapeutics' Debt to Equity history spans 4 years, with the latest figure at $0.89 for Q3 2023.

  • For Q3 2023, Debt to Equity rose 129.99% year-over-year to $0.89; the TTM value through Sep 2023 reached $0.89, up 129.99%, while the annual FY2022 figure was $0.42, 4749.19% up from the prior year.
  • Debt to Equity for Q3 2023 was $0.89 at Candel Therapeutics, up from $0.66 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.89 in Q3 2023 and bottomed at -$0.02 in Q4 2020.
  • The 4-year median for Debt to Equity is $0.39 (2022), against an average of $0.39.
  • The largest annual shift saw Debt to Equity skyrocketed 4749.19% in 2022 before it soared 63.49% in 2023.
  • A 4-year view of Debt to Equity shows it stood at -$0.02 in 2020, then surged by 144.43% to $0.01 in 2021, then surged by 4749.19% to $0.42 in 2022, then soared by 109.69% to $0.89 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Debt to Equity are $0.89 (Q3 2023), $0.66 (Q2 2023), and $0.51 (Q1 2023).